Abstract
Rituximab, a chimeric anti-CD20 monoclonal antibody, is used to treat rheumatologic and hematologic diseases. Serum sickness, a Type III delayed hypersensitivity reaction, has been reported with rituximab treatment. Traditionally, drug desensitization has been used to treat Type I IgE-mediated hypersensitivity reactions. We report the first case of successful drug desensitization to rituximab in a patient with medication-induced serum sickness. In our case, a 37-year-old woman with Sjogren’s syndrome and papillary thyroid carcinoma developed serum sickness 72 hours following rituximab infusion for gastric mucosal associated lymphoma tissue (MALT). Her MALT progressed after stopping rituximab. She underwent a rapid 12-step intravenous rituximab desensitization without recurrence of serum sickness. Following the completion of 4 rituximab desensitizations, she had gastric MALT remission. She received 25 maintenance rituximab doses using this desensitization protocol quarterly without complications. This is the first report documenting rituximab desensitization for the treatment of delayed drug reactions like serum sickness.
Keywords: Desensitization, hypersensitivity, mucosa associated lymphoid tissue, rituximab, serum sickness.
Current Drug Safety
Title:Desensitization Protocol for Rituximab-Induced Serum Sickness
Volume: 9 Issue: 3
Author(s): Merritt L. Fajt and Andrej A. Petrov
Affiliation:
Keywords: Desensitization, hypersensitivity, mucosa associated lymphoid tissue, rituximab, serum sickness.
Abstract: Rituximab, a chimeric anti-CD20 monoclonal antibody, is used to treat rheumatologic and hematologic diseases. Serum sickness, a Type III delayed hypersensitivity reaction, has been reported with rituximab treatment. Traditionally, drug desensitization has been used to treat Type I IgE-mediated hypersensitivity reactions. We report the first case of successful drug desensitization to rituximab in a patient with medication-induced serum sickness. In our case, a 37-year-old woman with Sjogren’s syndrome and papillary thyroid carcinoma developed serum sickness 72 hours following rituximab infusion for gastric mucosal associated lymphoma tissue (MALT). Her MALT progressed after stopping rituximab. She underwent a rapid 12-step intravenous rituximab desensitization without recurrence of serum sickness. Following the completion of 4 rituximab desensitizations, she had gastric MALT remission. She received 25 maintenance rituximab doses using this desensitization protocol quarterly without complications. This is the first report documenting rituximab desensitization for the treatment of delayed drug reactions like serum sickness.
Export Options
About this article
Cite this article as:
Fajt L. Merritt and Petrov A. Andrej, Desensitization Protocol for Rituximab-Induced Serum Sickness, Current Drug Safety 2014; 9 (3) . https://dx.doi.org/10.2174/1574886309666140509154056
DOI https://dx.doi.org/10.2174/1574886309666140509154056 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Occupational Allergy in Healthcare Workers
Recent Patents on Inflammation & Allergy Drug Discovery Inflammation-Mediating Proteases: Structure, Function in (Patho) Physiology and Inhibition
Protein & Peptide Letters Adverse Effects and Drug Interactions of Biologic Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Parvalbumin as a Pleomorphic Protein
Current Protein & Peptide Science The Role of Immunosuppressive Medications in the Pathogenesis of Hypertension and Efficacy and Safety of Antihypertensive Agents in Kidney Transplant Recipients
Current Medicinal Chemistry Perception of Symptoms in Hypertensive Patients and the Relevance to the Application of Anti- Hypertensive Drug Therapy
Current Pharmaceutical Design Topical Imiquimod: Mechanism of Action and Clinical Applications
Mini-Reviews in Medicinal Chemistry Current and Future Chemotherapy for Chagas Disease
Current Medicinal Chemistry Isolated Unilateral Tongue Oedema: The Adverse Effect of Angiotensin Converting Enzyme Inhibitors
Current Drug Safety Serum Albumin Complexation of Acetylsalicylic Acid Metabolites
Current Drug Metabolism Antibodies Against Complement System in SLE and their Potential Diagnostic Utility
Current Rheumatology Reviews Future Preventive and Therapeutic Targets for Transfusion-Related Acute Lung Injury
Current Pharmaceutical Design Pharmacotherapy for Smoking Cessation: Present and Future
Current Pharmaceutical Design Use of Alternative Antiplatelet Agents for Clopidogrel Hypersensitivity
Current Vascular Pharmacology Engineered Protein Protease Inhibitors
Current Enzyme Inhibition Pharmacological Interactions on Blood Pressure Control in Arterial Hypertension, An Issue not to be Overlooked
Cardiovascular & Hematological Disorders-Drug Targets Association of Wheat Allergy and Coeliac Disease through Pediatric and Adult Age: A Review of Literature
Current Nutrition & Food Science Aging and Remodeling During Healing of the Wounded Heart: Current Therapies and Novel Drug Targets
Current Drug Targets Small Peptides as Modulators of Serine Proteases
Current Medicinal Chemistry Target Product Selection - Where Can Molecular Pharming Make the Difference?
Current Pharmaceutical Design